Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medytox Inc.
Hugel Expects Acquisition By GS Consortium Won’t Deter Growth Strategy
Hugel says its longer-term global growth strategy will remain intact after a major acquisition of the Korean medical aesthetics company by a consortium including GS Group.
US Slashes Import Ban In Daewoong, Medytox Botulinum War
The USITC has issued a final determination in the long-running botulinum toxin dispute between Daewoong and Medytox, sharply cutting the length of Daewoong’s product import ban and reversing its initial decision with respect to Medytox’s bacterial strain. But the dispute seems poised to continue as Daewoong vows further legal steps.
ITC Takes Medytox’s Hand In US Botulinum Case, Bans Daewoong’s Imports
USITC’s initial decision in the Medytox and Daewoong botulinum dispute is favorable to Medytox and poised to take a toll on the Korean firm and partner Evolus as they face a 10-year ban on imports of their product to the US.
Korea Botox Rivalry To Intensify After Meditoxin Measures
As South Korea’s drug ministry decides to rescind approval of Medytox’s botulinum toxin product following manipulation of manufacturing and quality control documents, competition among existing rivals and newcomers is expected to further intensify.
- In Vitro Diagnostics
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.